Details of the Drug Combination

General Information of Drug Combination (ID: DCNQDSK)

Drug Combination Name
F901318 Fluconazole
Indication
Disease Entry Status REF
Invasive Aspergillosis Phase 1 [1]
Component Drugs F901318   DM2CUS0 Fluconazole   DMOWZ6B
Small molecular drug Small molecular drug
2D MOL 2D MOL
3D MOL 3D MOL

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)
Indication(s) of F901318
Disease Entry ICD 11 Status REF
Fungal infection 1F29-1F2F Phase 2 [2]
F901318 Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Aspergillus Dihydroorotate dehydrogenase (Aspergillus DHODH) TTTSUI2 G5EB61_EMENI Inhibitor [5]
------------------------------------------------------------------------------------
Indication(s) of Fluconazole
Disease Entry ICD 11 Status REF
Cryptococcal meningitis N.A. Approved [3]
Fungal infection 1F29-1F2F Approved [4]
Invasive candidiasis 1F23 Approved [3]
Mycoses 1F2Z Approved [3]
Oral candidiasis 1F23.0 Approved [3]
Autoimmune polyendocrine syndrome type 1 N.A. Investigative [3]
Candidemia 1F23.3Y Investigative [3]
Esophageal candidiasis N.A. Investigative [3]
Fluconazole Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Candida Cytochrome P450 51 (Candi ERG11) TTTSOUD CP51_CANAL Modulator [7]
------------------------------------------------------------------------------------
Fluconazole Interacts with 1 DME Molecule(s)
DME Name DME ID UniProt ID Mode of Action REF
Cytochrome P450 2C9 (CYP2C9) DE5IED8 CP2C9_HUMAN Metabolism [8]
------------------------------------------------------------------------------------
Fluconazole Interacts with 3 DOT Molecule(s)
DOT Name DOT ID UniProt ID Mode of Action REF
Steroidogenic acute regulatory protein, mitochondrial (STAR) OTFEZ5AI STAR_HUMAN Increases Expression [9]
ATP-dependent translocase ABCB1 (ABCB1) OTEJROBO MDR1_HUMAN Increases ADR [6]
Cytochrome P450 2C19 (CYP2C19) OTFMJYYE CP2CJ_HUMAN Increases Metabolism [10]
------------------------------------------------------------------------------------

References

1 ClinicalTrials.gov (NCT02730442) Study of Potential for Interaction of Fluconazole With F901318
2 ClinicalTrials.gov (NCT03583164) Evaluate F901318 Treatment of Invasive Fungal Infections in Patients Lacking Treatment Options (FORMULA-OLS). U.S. National Institutes of Health.
3 Fluconazole FDA Label
4 Fluconazole use as an important risk factor in the emergence of fluconazole-resistant Candida glabrata fungemia. Arch Intern Med. 2009 Aug 10;169(15):1444-5; author reply 1445.
5 Effect of the Novel Antifungal Drug F901318 (Olorofim) on Growth and Viability of Aspergillus fumigatus. Antimicrob Agents Chemother. 2018 Jul 27;62(8):e00231-18.
6 ADReCS-Target: target profiles for aiding drug safety research and application. Nucleic Acids Res. 2018 Jan 4;46(D1):D911-D917. doi: 10.1093/nar/gkx899.
7 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
8 Effect of fluconazole on plasma fluvastatin and pravastatin concentrations. Eur J Clin Pharmacol. 2000 Jun;56(3):225-9.
9 Fluconazole inhibits human adrenocortical steroidogenesis in vitro. J Endocrinol. 2012 Dec;215(3):403-12. doi: 10.1530/JOE-12-0310. Epub 2012 Oct 4.
10 [Simultaneous determination of the inhibitory potency of compounds on the activity of five cytochrome P-450 enzymes using a cocktail probe substrates method]. Yao Xue Xue Bao. 2007 Jun;42(6):589-94.